Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSV-IFNb-TYRP1 in Metastatic Melanoma
NCT03865212Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Jun 2019
- Primary completion
- Oct 2025
- Modality
- Gene Editing, Vaccines & Immunotherapeutics, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of VSV-IFNbeta-TYRP1 in melanoma (2 arms), sponsored by Mayo Clinic. Primary endpoints: Maximum-tolerated dose at 28 days and Incidence of adverse events at 28 days. Started Jun 2019; status: terminated.
02
Drugs
VSV-IFNbeta-TYRP1
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03865212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865212.